Get started
Vir Biotechnology, Inc.Vir Biotechnology, Inc.Vir Biotechnology, Inc.

Vir Biotechnology, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

VIR trade ideas

Vir Biotechnology | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # Vir Biotechnology - Entry Bias Hypothesis 1 | Center Settings - Entry Bias Hypothesis 2 | Supply Area - 12345 | Wave 1 | Failed Target - Retracement | 0618 & 0.5 Area | Infliction - Double Top Pattern | 0.382 Formation Active Sessions On Relevant Range & Elemented Probabilities; London(Upwards) - NYC(Downwards) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell
CAPITALCOM:VIRShort
by TradePolitics
VIR - long - catalyst / gap playVir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue. This is not a financial advice! 2 upcoming catalyst on 30rd of June 2024 and 1 in 2H 2024 and even more EOY We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work. 6.57% short float Rel. Vol. at 1.54 - it will increase in upcoming days / weeks imo Good news has been dropped We might see a little PB to around 11.0 where is a good entry - you could enter at 11.50 too if u want. Keep an eye on 14.0, 16.0 and 18.0 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains. SL under 9.5 TP approx. 22.0 Most info on the chart. Trade carefully!
NASDAQ:VIRLong
by meitshels_smell_trades
2
VIR -Analysts expect much more, but for now let's settle for~$22Still in a dangerous zone but breaking a resistance level after shuffling with supporting volume and oscillators returning to positive territory Buy - $11.3 First target - $14.45 Second target - around $22 If the stock reaches these numbers we will talk about additional goals, right now it's too early to talk. Not a recommendation of course! For those of you who do not have the appropriate experience, look at my signature below NASDAQ:VIR
NASDAQ:VIRLong
by maor_yeh
3
WATCH $VIRBullish Fundamental - High inflationary Macro environment / no fear sentiment - Funds Accumulation - Positive PE - Positive PEG - Positive P/FCF - Top Sector / Industry - Moderate floats - High short interest / 7 days + 58% - Impressive sales ? Technical - - Momentum Theory Indicator - N/A on the weekly - Price action formation ( falling wedge ) - Yet to break Trend line - Below 200MA - Above POC - Below ST Entry idea - For members Stop loss depending on entry and risk appetite. But always set meaningful stops. Consistency is what transforms average into excellence Cheers and happy trading!
NASDAQ:VIRLong
by nexxtrade
$VIR entry PT 42-44 Long term Target PT 200HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $200 CEO of Covid antibody maker Vir Biotech says its treatment ‘stands up well’ to all variants KEY POINTS: - Vir Biotechnology CEO George Scangos said the monoclonal antibody Covid treatment it developed with GlaxoSmithKline “stands up well” to all variants. - The companies announced contracts to sell $1 billion worth of sotrovimab to the U.S. government. The FDA has already granted sotrovimab an emergency use authorization to treat mild to moderate Covid infections. - Though Scangos said the delta variant is “going to be with us for a while,” he added that sotrovimab could likely protect against new variants that emerge. Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
NASDAQ:VIRLong
by BADQOMOCAWGOWLD
VIR - BREAKOUT IN THE HORIZON - POSSIBLY IN JAN/FEB 2022The VIR weekly chart shows an obvious resemblance between Phase 1 and Phase 2, so we can expect a breakout to $80-90 zone on good news, for example Q4 Earning report with Covid treatmengt Sotrovimab sales worldwide or good trial readouts from their developing products, when the Phase 2 completed. Note: VIR share price is heavily undervalued, the fair share value is $46. The company has good recent ERs. They have 1 billion in cash, no debt. Buy zone: $30-35, enter now after the last fall on the news on Pfizer's pill, but it will go through ups and downs before the possible spike or wait until Waves F, G completed (which is safer but you can miss the spike if you enter too late) Price Target: $80-85 in three months My ideas can be 100% wrong, please do your own DDs before entering a position with VIR or any other stocks Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; a collaboration, license, and option agreement with Visterra, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with Generation Bio., as well as GlaxoSmithKline Intellectual Property Development Limited, GlaxoSmithKline Biologicals SA., and Alnylam Pharmaceuticals, Inc. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies for potential COVID-19 treatment; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was founded in 2016 and is headquartered in San Francisco, California.
NASDAQ:VIRLong
by HannahN1512
8
Significant and Rapid Reduction in Hepatitis B Surface AntigenInitial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients. Additional data will be submitted for presentation at an upcoming medical conference. A Phase 2 trial combining VIR-3434 with Vir’s HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year. finance.yahoo.com
NASDAQ:VIR
by AlenCiken